Replies to post #324922 on Avid Bioservices Inc (CDMO)

[north40000]

Biopharm, note FDA approval of AZN’s D-mab in stage 3(early) NSCLC in past few days(saw report this past weekend myself). Combo trials with another mab(not CDMO’s) already started, with results to be reported later this year. RRRs(relative response rates) in patient population treated were not reported in what I read in AZN’s PR.

I have seen no follow-up on what I earlier said, per your quote.